Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Impact assessment of risk management interventions.

Shryock TR.

Rev Sci Tech. 2012 Apr;31(1):307-15. Review.

2.

Reversible monensin adaptation in Enterococcus faecium, Enterococcus faecalis and Clostridium perfringens of cattle origin: potential impact on human food safety.

Simjee S, Heffron AL, Pridmore A, Shryock TR.

J Antimicrob Chemother. 2012 Oct;67(10):2388-95. doi: 10.1093/jac/dks236. Epub 2012 Jun 27.

PMID:
22740589
3.

Pan-European monitoring of susceptibility to human-use antimicrobial agents in enteric bacteria isolated from healthy food-producing animals.

de Jong A, Thomas V, Simjee S, Godinho K, Schiessl B, Klein U, Butty P, Vallé M, Marion H, Shryock TR.

J Antimicrob Chemother. 2012 Mar;67(3):638-51. doi: 10.1093/jac/dkr539. Epub 2011 Dec 29.

PMID:
22210758
4.

Relationship of in vitro minimum inhibitory concentrations of tilmicosin against Mannheimia haemolytica and Pasteurella multocida and in vivo tilmicosin treatment outcome among calves with signs of bovine respiratory disease.

McClary DG, Loneragan GH, Shryock TR, Carter BL, Guthrie CA, Corbin MJ, Mechor GD.

J Am Vet Med Assoc. 2011 Jul 1;239(1):129-35. doi: 10.2460/javma.239.1.129.

PMID:
21718206
5.

Overview of the animal health drug development and registration process: an industry perspective.

Hunter RP, Shryock TR, Cox BR, Butler RM, Hammelman JE.

Future Med Chem. 2011 May;3(7):881-6. doi: 10.4155/fmc.11.55.

PMID:
21644833
6.

The interface between veterinary and human antibiotic use.

Shryock TR, Richwine A.

Ann N Y Acad Sci. 2010 Dec;1213:92-105. doi: 10.1111/j.1749-6632.2010.05788.x. Epub 2010 Oct 4. Review.

PMID:
20946576
7.

Influence of avilamycin administration and its subsequent withdrawal on emergence and disappearance of antimicrobial resistance in enterococci in the intestine of broiler chickens.

Silley P, Shryock TR, Simjee S, Fukumoto K.

J Appl Microbiol. 2007 Dec;103(6):2730-1; author reply 2732. No abstract available.

8.

Macrolide-resistant Campylobacter: the meat of the matter.

Belanger AE, Shryock TR.

J Antimicrob Chemother. 2007 Oct;60(4):715-23. Epub 2007 Aug 18. Review.

PMID:
17704515
9.

Agar dilution and disk diffusion susceptibility testing of Campylobacter spp.

Fritsche TR, McDermott PF, Shryock TR, Walker RD, Morishita TY.

J Clin Microbiol. 2007 Aug;45(8):2758-9; author reply 2759. No abstract available.

10.

Letter to the editor: comments on a recent article by Burgos et al.

Shryock TR, Watts JL, Gray JT.

J Dairy Sci. 2005 Dec;88(12):4136. No abstract available.

11.

Internationally recognized antimicrobial susceptibility testing methods and interpretive criteria: the case for conformity.

Shryock TR.

J Infect Dis. 2005 Dec 1;192(11):2027-8; author reply 2028-9. No abstract available.

PMID:
16267777
12.

Animal health pharmaceutical industry.

Carnevale RA, Shryock TR.

Prev Vet Med. 2006 Feb 24;73(2-3):217-20. Epub 2005 Nov 2.

PMID:
16266763
13.

Avilamycin did not play a role in the discontinuation of evernimicin as a clinical drug candidate.

Belanger AE, Shryock TR.

J Mass Spectrom. 2005 Aug;40(8):1109. No abstract available.

PMID:
16041736
14.

The future of anti-infective products in animal health.

Shryock TR.

Nat Rev Microbiol. 2004 May;2(5):425-30. Review. No abstract available.

PMID:
15100695
16.

Prevalence of a novel capsule-associated lipoprotein among pasteurellaceae pathogenic in animals.

Champlin FR, Shryock TR, Patterson CE, Austin FW, Ryals PE.

Curr Microbiol. 2002 Apr;44(4):297-301.

PMID:
11910502
17.

Will avilamycin convert ziracine into zerocine?

Shryock TR.

Emerg Infect Dis. 2001 May-Jun;7(3):488-9. No abstract available.

18.

In vitro susceptibility of porcine respiratory pathogens to tilmicosin.

DeRosa DC, Veenhuizen MF, Bade DJ, Shryock TR.

J Vet Diagn Invest. 2000 Nov;12(6):541-6.

PMID:
11108454
19.

Antimicrobial susceptibility of Mycoplasma hyorhinis.

Wu CC, Shryock TR, Lin TL, Faderan M, Veenhuizen MF.

Vet Microbiol. 2000 Sep 15;76(1):25-30.

PMID:
10925038
20.
21.
22.
23.

Comparison of tilmicosin and cephapirin as therapeutics for Staphylococcus aureus mastitis at dry-off.

Nickerson SC, Owens WE, Fox LK, Scheifinger CC, Shryock TR, Spike TE.

J Dairy Sci. 1999 Apr;82(4):696-703.

25.

Computed axial tomography of the porcine nasal cavity and a morphometric comparison of the nasal turbinates with other visualization techniques.

Shryock TR, Losonsky JM, Smith WC, Gatlin CL, Francisco CJ, Kuriashkin IV, Clarkson RB, Jordan WH.

Can J Vet Res. 1998 Oct;62(4):287-92.

26.
27.

Intracellular accumulation, subcellular distribution and efflux of tilmicosin in swine phagocytes.

Scorneaux B, Shryock TR.

J Vet Pharmacol Ther. 1998 Aug;21(4):257-68.

PMID:
9731947
28.

Antimicrobial susceptibility of Moraxella bovis.

Shryock TR, White DW, Werner CS.

Vet Microbiol. 1998 Apr 15;61(4):305-9.

PMID:
9646479
29.

The effects of macrolides on the expression of bacterial virulence mechanisms.

Shryock TR, Mortensen JE, Baumholtz M.

J Antimicrob Chemother. 1998 May;41(5):505-12. Review.

PMID:
9630404
30.
31.

In-vitro antimicrobial susceptibility of Clostridium perfringens from commercial turkey and broiler chicken origin.

Watkins KL, Shryock TR, Dearth RN, Saif YM.

Vet Microbiol. 1997 Feb;54(2):195-200.

PMID:
9057262
34.

The quantitation of turbinate atrophy in pigs to measure the severity of induced atrophic rhinitis.

Gatlin CL, Jordan WH, Shryock TR, Smith WC.

Can J Vet Res. 1996 Apr;60(2):121-6.

35.

Synthesis, antimicrobial activity and in vivo fluorine NMR of a hexafluorinated derivative of tilmicosin.

Creemer LC, Kirst HA, Shryock TR, Campbell JB, Webb AG.

J Antibiot (Tokyo). 1995 Jul;48(7):671-5.

36.

Proposed quality control guidelines for antimicrobial susceptibility tests using tilmicosin.

Shryock TR, White DW, Werner CS, Staples JM.

J Clin Microbiol. 1995 Feb;33(2):331-5.

37.

Characterization of an Actinobacillus pleuropneumoniae seeder pig challenge-exposure model.

Lechtenberg KF, Shryock TR, Moore G.

Am J Vet Res. 1994 Dec;55(12):1703-9.

PMID:
7887514
38.
39.

The accumulation of bactericidal lipids in staphylococcal abscesses.

Shryock TR, Dye ES, Kapral FA.

J Med Microbiol. 1992 May;36(5):332-6.

PMID:
1588583
40.

Modification of bactericidal fatty acids by an enzyme of Staphylococcus aureus.

Mortensen JE, Shryock TR, Kapral FA.

J Med Microbiol. 1992 Apr;36(4):293-8.

PMID:
1560452
41.

The production of bactericidal fatty acids from glycerides in staphylococcal abscesses.

Shryock TR, Kapral FA.

J Med Microbiol. 1992 Apr;36(4):288-92.

PMID:
1560451
42.

Antimicrobial susceptibility of Bordetella avium and Bordetella bronchiseptica isolates.

Mortensen JE, Brumbach A, Shryock TR.

Antimicrob Agents Chemother. 1989 May;33(5):771-2.

43.

Supplemental Content

Loading ...
Support Center